DaVita Inc. specializes in delivering essential kidney dialysis treatments and comprehensive renal care to individuals grappling with chronic kidney failure. The company primarily operates an extensive network of outpatient dialysis centers, supplementing this with services provided in hospital inpatient settings and within patients' homes. Beyond direct patient treatment, DaVita manages its own diagnostic laboratories, performing routine tests vital for dialysis patients, alongside other physician-ordered laboratory analyses specifically for those with end-stage renal disease (ESRD). The firm also offers administrative and management support to various other outpatient dialysis facilities. Its broad spectrum of offerings extends to chronic disease management programs, supporting a substantial patient cohort; by year-end 2021, this included 16,000 patients enrolled in risk-based integrated care models and an additional 7,000 in other integrated care arrangements. Further specialized services encompass vascular access interventions, clinical research initiatives, direct physician support, and a complete suite of holistic kidney care solutions. As of December 31, 2021, DaVita's footprint across the United States comprised 2,815 outpatient dialysis centers, collectively serving approximately 203,100 patients. Globally, the company operated 339 outpatient dialysis centers spread across ten countries outside the U.S., attending to roughly 39,900 patients. Moreover, it furnished acute inpatient dialysis services and related laboratory work in around 850 U.S. hospitals. Founded in 1994, DaVita Inc. maintains its headquarters in Denver, Colorado. The company rebranded to its current name in September 2016, having previously been known as DaVita HealthCare Partners Inc.
前日終値
$177.02
+$0.24 · +0.14%
日中の時刻はETです。市場データは遅延する場合があります。
DaVita Inc. specializes in delivering essential kidney dialysis treatments and comprehensive renal care to individuals grappling with chronic kidney failure. The company primarily operates an extensive network of outpatient dialysis centers, supplementing this with services provided in hospital inpatient settings and within patients' homes. Beyond direct patient treatment, DaVita manages its own diagnostic laboratories, performing routine tests vital for dialysis patients, alongside other physician-ordered laboratory analyses specifically for those with end-stage renal disease (ESRD). The firm also offers administrative and management support to various other outpatient dialysis facilities. Its broad spectrum of offerings extends to chronic disease management programs, supporting a substantial patient cohort; by year-end 2021, this included 16,000 patients enrolled in risk-based integrated care models and an additional 7,000 in other integrated care arrangements. Further specialized services encompass vascular access interventions, clinical research initiatives, direct physician support, and a complete suite of holistic kidney care solutions. As of December 31, 2021, DaVita's footprint across the United States comprised 2,815 outpatient dialysis centers, collectively serving approximately 203,100 patients. Globally, the company operated 339 outpatient dialysis centers spread across ten countries outside the U.S., attending to roughly 39,900 patients. Moreover, it furnished acute inpatient dialysis services and related laboratory work in around 850 U.S. hospitals. Founded in 1994, DaVita Inc. maintains its headquarters in Denver, Colorado. The company rebranded to its current name in September 2016, having previously been known as DaVita HealthCare Partners Inc.
日中レンジ
現在 $177.02
52週レンジ
現在 $177.02
日中の時刻はETです。市場データは遅延する場合があります。
GoAI スコア
中立
バリュエーション
54
適正価値
センチメント
60
まちまち
リスク
20
低リスク
モメンタム
72
上昇基調
GoAIの詳細リサーチ
詳しい根拠、カタリスト、リスクを確認できます。
DaVita Inc. specializes in delivering essential kidney dialysis treatments and comprehensive renal care to individuals grappling with chronic kidney failure. The company primarily operates an extensive network of outpatient dialysis centers, supplementing this with services provided in hospital inpatient settings and within patients' homes. Beyond direct patient treatment, DaVita manages its own diagnostic laboratories, performing routine tests vital for dialysis patients, alongside other physician-ordered laboratory analyses specifically for those with end-stage renal disease (ESRD). The firm also offers administrative and management support to various other outpatient dialysis facilities. Its broad spectrum of offerings extends to chronic disease management programs, supporting a substantial patient cohort; by year-end 2021, this included 16,000 patients enrolled in risk-based integrated care models and an additional 7,000 in other integrated care arrangements. Further specialized services encompass vascular access interventions, clinical research initiatives, direct physician support, and a complete suite of holistic kidney care solutions. As of December 31, 2021, DaVita's footprint across the United States comprised 2,815 outpatient dialysis centers, collectively serving approximately 203,100 patients. Globally, the company operated 339 outpatient dialysis centers spread across ten countries outside the U.S., attending to roughly 39,900 patients. Moreover, it furnished acute inpatient dialysis services and related laboratory work in around 850 U.S. hospitals. Founded in 1994, DaVita Inc. maintains its headquarters in Denver, Colorado. The company rebranded to its current name in September 2016, having previously been known as DaVita HealthCare Partners Inc.
日中レンジ
現在 $177.02
52週レンジ
現在 $177.02
利用可能な期間全体で報告されたマージン。
売上高
営業利益
純利益
| 指標(USD) | 2025年度 | 2024年度 | 2023年度 | 2022年度 | 2021年度 |
|---|---|---|---|---|---|
| 売上高 | 136.43億 USD | 128.16億 USD | 121.4億 USD | 116.1億 USD | 116.19億 USD |
| 売上原価 | 99.59億 USD | 85.99億 USD | 83.2億 USD | 82.1億 USD | 79.72億 USD |
| 粗利益 | 36.84億 USD | 42.17億 USD | 38.2億 USD | 34億 USD | 36.46億 USD |
| 販売・一般管理 | 16.74億 USD | 15.38億 USD | 14.74億 USD | 13.55億 USD | 11.95億 USD |
| 営業費用 | 16.74億 USD | 21.27億 USD | 22.18億 USD | 20.61億 USD | 18.49億 USD |
| 支払利息 | 5.5億 USD | 4.7億 USD | 3.99億 USD | 3.57億 USD | 2.85億 USD |
| 減価償却費と償却費 | 7.15億 USD | 7.24億 USD | 7.45億 USD | 7.33億 USD | 6.81億 USD |
| 営業利益 | 20.11億 USD | 20.9億 USD | 16.03億 USD | 13.39億 USD | 17.97億 USD |
| 純利益 | 7.47億 USD | 9.36億 USD | 6.92億 USD | 5.6億 USD | 9.78億 USD |
会社概要が更新されました 2026年10月9日.
直近の発表実績
直近の発表実績
第三者のアナリスト予想は変更される場合があり、GoAIの推奨ではありません。
平均目標
$235.67
上昇余地(33.13%)| 種別 | 発効日 | 詳細 | 基準日 | 支払日 |
|---|---|---|---|---|
株式分割 | 2013年9月9日 | 2:1 | — | — |
株式分割 | 2004年6月16日 | 3:2 | — | — |
株式分割 | 1997年10月21日 | 5:3 | — | — |
発効済み 2013年9月9日
2:1
発効済み 2004年6月16日
3:2
発効済み 1997年10月21日
5:3
この株式へのエクスポージャーを報告している上場投資信託です。
State Street SPDR S&P 500 ETF1557.T115.24億0.01%129.69兆 JPY0.09%¥122,850+0.12%
Invesco S&P 500 Equal Weight ETFRSP1.89億0.20%962.01億 USD0.20%$211.87+0.60%
Vanguard Morningstar Total Stock Market ETFVTI1.8億0.01%2.3兆 USD0.03%$379.56-0.39%
Vanguard S&P 500 ETFVOO1.5億0.01%1.8兆 USD0.03%$711.28-0.43%
Vanguard Morningstar Small-Cap ETFVB1.3億0.07%1853億 USD0.03%$287.63+0.23%
Vanguard Morningstar Small-Cap Value ETFVBR8255.82万0.12%682億 USD0.05%$233.91+0.75%
iShares Core S&P 500 ETFIVV7959.13万0.01%8972.05億 USD0.03%$777.27-0.42%
State Street SPDR S&P 500 ETFSPY7284.53万0.01%8215.35億 USD0.09%$773.93-0.42%
State Street SPDR S&P 500 ETF1557.T
Invesco S&P 500 Equal Weight ETFRSP
Vanguard Morningstar Total Stock Market ETFVTI
Vanguard S&P 500 ETFVOO
Vanguard Morningstar Small-Cap ETFVB
Vanguard Morningstar Small-Cap Value ETFVBR
iShares Core S&P 500 ETFIVV
State Street SPDR S&P 500 ETFSPYAIが生成した遅延市場データを、情報提供および教育目的で掲載しています。投資助言ではありません。